Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Invesco

PBE Holdings: What Invesco Biotechnology & Genome ETF Owns

Ticker PBE · Since 2005-06-23 · · Holdings as of Jul 31, 2026

Expense ratio
0.59%$59/yr per $10k
5-yr return
+3.4%annualized
1-yr return
+24.7%as of Dec 2025
Net assets
$281.9Mall share classes
Holdings
33

Bottom line

What does PBE hold?

PBE held 33 positions as of Jul 31, 2026. Its largest holding is Invesco Private Prime Fund at 12.89% of the fund, and the top 10 positions add up to 56.8%. By asset type it is 100% stocks, 18% cash & short-term funds.

Updated Sep 28, 2026

PBE top 25 holdings

#HoldingType% of fundValue
1 Invesco Private Prime Fund Cash & short-term funds 12.89%$36.3M
2 Regeneron Pharmaceuticals, Inc. Stocks 5.47%$15.4M
3 Amgen Inc. Stocks 5.22%$14.7M
4 CareDx, Inc. Stocks 5.04%$14.2M
5 Vertex Pharmaceuticals Inc. Stocks 4.99%$14.1M
6 Invesco Private Government Fund Cash & short-term funds 4.97%$14.0M
7 Royalty Pharma PLC
Royalty Pharma PLC, Class A
Stocks 4.94%$13.9M
8 Biogen Inc. Stocks 4.79%$13.5M
9 Gilead Sciences, Inc. Stocks 4.43%$12.5M
10 United Therapeutics Corp. Stocks 4.08%$11.5M
11 Bio-Techne Corp. Stocks 3.73%$10.5M
12 Illumina, Inc. Stocks 3.51%$9.9M
13 Protagonist Therapeutics, Inc. Stocks 3.40%$9.6M
14 Vericel Corp. Stocks 3.27%$9.2M
15 Alnylam Pharmaceuticals, Inc. Stocks 3.17%$8.9M
16 Incyte Corp. Stocks 3.06%$8.6M
17 Repligen Corp. Stocks 3.04%$8.6M
18 Acadia Pharmaceuticals Inc. Stocks 3.02%$8.5M
19 Halozyme Therapeutics, Inc. Stocks 2.98%$8.4M
20 Qiagen N.V. Stocks 2.89%$8.2M
21 BioMarin Pharmaceutical Inc. Stocks 2.82%$8.0M
22 Neurocrine Biosciences, Inc. Stocks 2.66%$7.5M
23 Exelixis, Inc. Stocks 2.64%$7.4M
24 BioCryst Pharmaceuticals, Inc. Stocks 2.63%$7.4M
25 Veracyte, Inc. Stocks 2.60%$7.3M

Source: SEC Form N-PORT, period ended Jul 31, 2026, filed Sep 28, 2026

Asset mix

Stocks100.1%
Cash & short-term funds17.9%

Country exposure

GB4.9%
KY1.6%
NL2.9%
US108.6%